| answer text |
<p>The following treatments are routinely available, having undergone Technical Appraisals
by the National Institute for Health and Care Excellence (NICE). They were previously
accessible through the Cancer Drugs Fund.</p><p> </p><p>- Blinatumomab for relapsed
refractory (r/r) Philadelphia negative acute lymphoblastic leukaemia (ALL); and</p><p>-
Ponatinib for Philadelphia positive ALL in patients in whom imatinib is not clinically
appropriate (which might cover some r/r).</p><p> </p><p>The following treatments are
currently under consideration by NICE:</p><p> </p><p>- CAR-T (Tisagenlecleucel-T and
also Axicabtagene ciloleucel) for previously treated B-cell ALL in people aged 3 to
21 at initial diagnosis;</p><p>- Inotuzumab ozogamicin for treating r/r ALL; and</p><p>-
Blinatumomab in other extended indications in ALL.</p><p> </p><p>Finally, the following
treatments are currently accessible through the Cancer Drugs Fund.</p><p> </p><p>-
Clofarabine for treating ALL in children after two therapies; and</p><p>- Nelarabine
for treating ALL after two therapies.</p><p> </p><p>Information on the number and
proportion of patients with refractory B-cell Acute Lymphoblastic Leukaemia who have
been unable to access treatments for that condition is not held centrally.</p>
|
|
